Proteolysis targeting chimeras (PROTACs) is the recently emerged field in drug discovery. This new approach works through the activation of the ubiquitin-proteasome system to remove disease-causing proteins. This new modality of therapeutic intervention requires new chemistry and new approaches to synthesize functional PROTAC molecules. Several recent papers of Oprea and Cravatt examined chemical space and ligandable proteome to evaluate a state of the targeted human genome. Herein we offer known and novel building blocks (E3 ligase ligands, ligands with linkers, linkers) for the synthesis of PROTACs.

You can find all structures we provided at MedChem Highlights section of our webpage.